Enertu+perzumabはHH2陽性の乳がんの生存率を著しく高めた. New drug combo Enhertu plus pertuzumab significantly boosts survival in HER2-positive breast cancer.

Enertu+perzumabは,標準的治療と比較して,HE2-陽性性乳がんの治療が著しく改善されていることを示している. A new drug combination, Enhertu plus pertuzumab, has shown significant improvements in treating HER2-positive metastatic breast cancer compared to standard treatments. この併用療法は,患者の生存率が著しく増加していることが判明し,十年以上で初めての改善が認められた. This combination therapy was found to notably increase progression-free survival in patients, marking the first such improvement in over a decade. HH2-陽性の乳がんは,全ての乳がん患者の約15%に影響を及ぼす. HER2-positive breast cancer affects about 15-20% of all breast cancer cases.